Discovery Projects - Grant ID: DP0208535

Funded Activity Summary

Molecular basis for the synergistic potentiation of anthracycline anticancer agents by formaldehyde-releasing prodrugs. AIMS: The overall aim is to develop a full understanding of the molecular basis for the synergistic activation of Adriamycin (and other anthracycline anticancer agents) by formaldehyde-releasing prodrugs such as AN-9. SIGNIFICANCE: Because Adriamycin is currently one of the most widely used anticancer agents, and this activity has the potential to be dramatically enhanced by the concurrent use of formaldehyde-releasing prodrugs, a biochemical understanding of these processes will provide the basis to exploit this synergy to provide improved treatment outcomes (eg, lower drug doses,reduced side-effects, improved activity against drug-resistanct tumours etc). EXPECTED OUTCOMES: The long-term outcome of this project is commercialisation to develop products for clinical use based on this synergy (eg, drug/prodrug combinations) and ultimately the development of tumour-directed therapy to yield a tumour-localised anticancer response.

Funded Activity Details

Start Date: 31-01-2002

End Date: 31-08-2007

Funding Scheme: Discovery Projects

Funding Amount: $689,782.00

Funder: Australian Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Biochemistry: Nucleic Acids | Medical Biochemistry and Metabolomics | Clinical Pharmacology And Therapeutics |

ANZSRC Socio-Economic Objective (SEO)

Cancer and related disorders

Other Keywords

Cancer and related disorders | Clinical Pharmacology And Therapeutics | Medical Biochemistry and Metabolomics | Medical Biochemistry: Nucleic Acids

Related Links